Qube Research & Technologies Ltd Grows Position in Mylan NV (NASDAQ:MYL)
Qube Research & Technologies Ltd raised its holdings in Mylan NV (NASDAQ:MYL) by 80.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,387 shares of the company’s stock after acquiring an additional 12,629 shares during the period. Qube Research & Technologies Ltd’s holdings in Mylan were worth $540,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in Mylan by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,120,516 shares of the company’s stock valued at $167,704,000 after acquiring an additional 538,334 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Mylan by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock worth $215,460,000 after purchasing an additional 1,026,731 shares in the last quarter. Retirement Systems of Alabama boosted its position in shares of Mylan by 1.0% in the 1st quarter. Retirement Systems of Alabama now owns 240,100 shares of the company’s stock worth $6,804,000 after purchasing an additional 2,340 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Mylan by 10.4% in the 1st quarter. Nisa Investment Advisors LLC now owns 96,001 shares of the company’s stock worth $2,721,000 after acquiring an additional 9,067 shares during the last quarter. Finally, Regent Investment Management LLC raised its stake in Mylan by 22.8% in the 1st quarter. Regent Investment Management LLC now owns 64,025 shares of the company’s stock worth $1,814,000 after acquiring an additional 11,900 shares during the last quarter. 83.27% of the stock is currently owned by hedge funds and other institutional investors.
Shares of MYL stock traded up $0.51 during trading on Monday, hitting $19.04. 99,373 shares of the stock traded hands, compared to its average volume of 10,912,588. The firm has a market capitalization of $9.08 billion, a P/E ratio of 4.15, a price-to-earnings-growth ratio of 0.83 and a beta of 1.77. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.37 and a quick ratio of 0.77. The firm’s fifty day moving average price is $19.09 and its 200-day moving average price is $23.55. Mylan NV has a 52-week low of $16.63 and a 52-week high of $39.59.
In other news, Director Robert J. Coury bought 49,859 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was purchased at an average price of $20.06 per share, for a total transaction of $1,000,171.54. Following the completion of the purchase, the director now owns 947,194 shares in the company, valued at approximately $19,000,711.64. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sjoerd S. Vollebregt bought 10,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were purchased at an average price of $19.11 per share, with a total value of $191,100.00. Following the purchase, the director now owns 18,258 shares of the company’s stock, valued at approximately $348,910.38. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 63,859 shares of company stock valued at $1,275,152. Insiders own 0.82% of the company’s stock.
Several equities research analysts recently issued reports on MYL shares. Raymond James set a $31.00 price objective on Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Evercore ISI restated a “buy” rating on shares of Mylan in a report on Friday, August 9th. UBS Group lowered their target price on Mylan to $23.00 and set a “neutral” rating on the stock in a report on Tuesday, May 28th. Morgan Stanley restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of Mylan in a report on Tuesday, July 30th. Finally, Zacks Investment Research upgraded Mylan from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $30.43.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.